A multinational research team has revealed how a tryptophan-rich allosteric communication network regulates receptor dynamics ...

Most protein-targeting drugs are prizes that drug developers have unearthed from G protein–coupled receptor (GPCR) interactomes. So, when GPCR-targeting drugs become harder to find, one might liken ...

Recent years have seen major advances in understanding the structure-function relationships of G protein-coupled receptors (GPCRs). This large superfamily of transmembrane receptors comprises over 800 ...

Septerna has secured $150 million in a series B fundraise, money that will go toward two newly unveiled programs including moving its first G-protein-coupled receptor (GPCR) drug into the clinic. The ...

Commercial sales and marketing agreement enhances 3RnD’s mechanistic toxicity screening panel, and expands the reach of ...

Septerna just entered the clinic, and its lack of human data makes it an outlier among the companies able to successfully go public this year in what is still a cautious biotech IPO market. What the ...

G protein-coupled receptors (GPCRs) represent the largest family of membrane proteins and one of the most successful therapeutic targets in modern medicine, with approximately 34% of FDA-approved ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, a biotechnology company discovering and advancing novel, oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today ...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness ...

The company states: “Exicure (XCUR) has announced the signing of a Memorandum of Understanding, MOU, with GPCR Therapeutics on December 24, 2024, aimed at the acquisition of GPCR USA, a subsidiary of ...

Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader ...